Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 19/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | ROS1 | P08922 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.52 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.52 |
| ▸ | CD63 | P08962 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23911870 | 0.90 | SYK (0.57) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL23911874 | 0.89 | SYK (0.58) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL23911868 | 0.87 | SYK (0.50) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL23911875 | 0.87 | SYK (0.54) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2896174 | 0.83 | SYK (0.64) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2478783 | 0.79 | SYK (0.69) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2481481 | 0.78 | SYK (0.62) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL23911855 | 0.78 | AURKA (0.49) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL21471585 | 0.78 | AURKA (0.63) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2482472 | 0.73 | SYK (0.67) | SYKJAK2NTRK1ROS1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002318-A1 | HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| US-11142535-B2 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142535-B2 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor | SYK, HDAC1, HDAC2 | SYK 1/4885JAK2 92/4885NTRK1 2622/4885 |
| US-20220002318-A1 | HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR | SYK, HDAC1, HDAC2 | SYK 1/4885JAK2 92/4885NTRK1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.